DUBLIN–(BUSINESS WIRE)–The “Medical Device CRO Market: Industry Trends and Global Forecasts, Till 2035 – Distribution by Target Therapeutic Area, Scale of OperationDUBLIN–(BUSINESS WIRE)–The “Medical Device CRO Market: Industry Trends and Global Forecasts, Till 2035 – Distribution by Target Therapeutic Area, Scale of Operation

Navigating the $19.3 Billion Medical Device CRO Market, 2025-2035: Mergers and Acquisitions Boost Geographical Consolidation – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Medical Device CRO Market: Industry Trends and Global Forecasts, Till 2035 – Distribution by Target Therapeutic Area, Scale of Operation, Device Class, Type of Clinical Service Offered, Type of Preclinical Service Offered and Key Geographies” has been added to ResearchAndMarkets.com’s offering.

The global medical device CRO market is projected to grow from USD 13.3 billion in the current year to USD 19.3 billion by 2035, driven by a significant CAGR during the forecast period. This growth is largely fueled by the increasing elderly population and the prevalence of chronic illnesses, sparking a demand for innovative medical devices. Since 2020, the USFDA has approved approximately 105 medical devices, with over 35 gaining approval each year. However, the industry faces hurdles, including a complex and resource-demanding product development phase, enhanced by regulatory mandates ensuring medical devices’ safety, which complicate operations for industry leaders.

To navigate these challenges, medical device developers increasingly outsource research activities to specialized CROs, which excel in handling clinical studies, regulatory demands, and safety compliance. These organizations facilitate the transition of innovative concepts to market, efficiently managing the product development lifecycle. The rapid integration of advanced technologies and tools, like risk monitoring systems and cloud computing, is reshaping the medical device landscape, forecasting significant growth for the CRO market in the coming decade.

Key insights from the report reveal that over 590 CROs claim competency in offering diverse research and analytical services for medical devices. The market is notably fragmented, with various players across different regions providing services for a range of device classes. CROs are continuously enhancing their capabilities to better their service offerings, evident in strategic mergers and acquisitions, where 53% target geographical consolidation. Over 14,000 trials involving approximately 4.6 million patients with various conditions are registered worldwide to assess medical devices’ efficacy and accuracy. The market’s steady growth is expected, propelled by stakeholders’ ongoing efforts.

The market segmentation reveals that clinical operations currently command the largest share. Notably, the clinical services sector remains dominant due to rising clinical trials on medical devices. Meanwhile, Class II devices are poised as the fastest-growing segment. In preclinical services, biocompatibility testing emerges as the fastest-growing type, though sterility and microbial testing hold a significant market share. CNS disorders dominate the therapeutic area segment, reflecting a substantial part of the device CRO market. Geographically, North America leads the charge with the largest market share, though other regions are expected to grow at higher CAGRs over the years.

Prominent players within this space include Avania, Charles River Laboratories, CROMSOURCE, CSSi LifeSciences, Eurofins Medical Testing, IQVIA, Medpace, NAMSA, Qserve Group, and WuXi AppTec. The research report, bolstered by conversations with various industry stakeholders, investigates several factors, including market sizing, competitive benchmarking, regulatory landscapes, and clinical trials analysis.

The study addresses critical questions like the number of active companies, leading market players, influencers on market evolution, and market size forecasts. It offers a comprehensive market overview, including SWOT analysis, to guide stakeholders in making informed decisions. Additional benefits include complimentary PPT insights, Excel data packs, and content customization, coupled with report walkthrough sessions for detailed understanding, ensuring stakeholders are well-equipped to navigate and excel in the medical device CRO market.

Key Topics Covered

Section I: Report Overview

1. Preface

2. Research Methodology

3. Market Dynamics

4. Macro-Economic Indicators

Section II: Qualitative Insights

5. Executive Summary

6. Introduction

7. Regulatory and Reimbursement Landscape for Medical Devices

Section III: Competitive Landscape

8. Medical Device Preclinical CROs: Market Landscape

9. Medical Device Clinical CROs: Market Landscape

10. Brand Positioning Analysis: Preclinical Medical Device CROs

11. Competitive Benchmarking: Clinical CROs

Section IV: Company Profiles

12. Company Profiles

Section V: Market Trends

13. Mergers and Acquisitions

14. Clinical Trial Analysis

15. Future Trends and Opportunities

Section VI: Market Forecast and Opportunity Analysis

16. SWOT Analysis

17. Global Medical Device CRO Market

18. Medical Device CRO Market, by Class of Medical Device

19. Medical Device CRO Market, by Type of Medical Device

20. Medical Device CRO Market, by Scale of Operation

21. Medical Device CRO Market, by Type of Preclinical Service Offered

22. Medical Device CRO Market, by Type of Clinical Service Offered

23. Medical Device CRO Market, by Company Size

24. Medical Device CRO Market, by Type of Original Equipment Manufacturer

25. Medical Device CRO Market, by Target Indication

26. Medical Device CRO Market, by Geographical Regions

27. Medical Device CRO Market, by Leading Players

Section VII: Case Study

28. Medical Device Developer and CRO Relationships: Key Value Drivers and Performance Indicators

29. Total Cost of Ownership for Medical Devices CROs

30. Case Study: List of Additional Medical Device CROs

Section VIII: Other Exclusive Insights

31. Conclusion

32. Executive Insights

Section IX: Appendices

33. Appendix I: Tabulated Data

34. Appendix II: List of Additional Medical Device Clinical CROs

35. Appendix III: List of Companies and Organizations

A selection of companies mentioned in this report includes, but is not limited to:

  • 1MED
  • 4Clinics
  • 4Pharma
  • A+ Science
  • Abiogenesis Clinpharm
  • Abond CRO
  • Absorption Systems
  • ABX-CRO
  • Acceliant
  • Accell Clinical Research
  • AccelLAB
  • Accelovance
  • Accredited Consultants
  • AccuLab Life Sciences
  • Accuprec Research Labs
  • Accutest Research Laboratories
  • Acorn Regulatory
  • Acrapack
  • acromion
  • aCROss Medical
  • ACT FARMA CRO
  • Activa Cro
  • ADAX International
  • Advanced Drug Development Services
  • Advanced Medical Research
  • Advena
  • Affinity Bio Partners
  • Afortiori Development
  • Afra Pharma Consultant
  • Aginko Research
  • AICROS
  • CETERA
  • AIX Scientifics
  • AJW Technology Consultants
  • AKRN
  • Al Tamimi & Company
  • Alera Labs
  • Alira Health
  • Allied Clinical Management
  • Altair Clinical
  • Altasciences
  • Altiora
  • AlvaMed
  • Amarex
  • American Preclinical Services (Acquired by NAMSA)
  • and many, many more!

For more information about this report visit https://www.researchandmarkets.com/r/ckgb1w

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Market Opportunity
Cronos Logo
Cronos Price(CRO)
$0.09365
$0.09365$0.09365
+1.10%
USD
Cronos (CRO) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

The Top 10 Altcoins Most Purchased by Investors in 2025 Have Been Revealed! There’s a Trump Detail Too!

The Top 10 Altcoins Most Purchased by Investors in 2025 Have Been Revealed! There’s a Trump Detail Too!

The post The Top 10 Altcoins Most Purchased by Investors in 2025 Have Been Revealed! There’s a Trump Detail Too! appeared on BitcoinEthereumNews.com. The Top
Share
BitcoinEthereumNews2025/12/25 17:36
The high premium of silver funds has attracted attention; Guotou Silver LOF will be suspended from trading from the opening of the market on December 26 until 10:30 a.m. on the same day.

The high premium of silver funds has attracted attention; Guotou Silver LOF will be suspended from trading from the opening of the market on December 26 until 10:30 a.m. on the same day.

PANews reported on December 25th that Guotou Silver LOF announced it will suspend trading from the market opening on December 26th until 10:30 AM, resuming trading
Share
PANews2025/12/25 17:10
Why The Green Bay Packers Must Take The Cleveland Browns Seriously — As Hard As That Might Be

Why The Green Bay Packers Must Take The Cleveland Browns Seriously — As Hard As That Might Be

The post Why The Green Bay Packers Must Take The Cleveland Browns Seriously — As Hard As That Might Be appeared on BitcoinEthereumNews.com. Jordan Love and the Green Bay Packers are off to a 2-0 start. Getty Images The Green Bay Packers are, once again, one of the NFL’s better teams. The Cleveland Browns are, once again, one of the league’s doormats. It’s why unbeaten Green Bay (2-0) is a 8-point favorite at winless Cleveland (0-2) Sunday according to betmgm.com. The money line is also Green Bay -500. Most expect this to be a Packers’ rout, and it very well could be. But Green Bay knows taking anyone in this league for granted can prove costly. “I think if you look at their roster, the paper, who they have on that team, what they can do, they got a lot of talent and things can turn around quickly for them,” Packers safety Xavier McKinney said. “We just got to kind of keep that in mind and know we not just walking into something and they just going to lay down. That’s not what they going to do.” The Browns certainly haven’t laid down on defense. Far from. Cleveland is allowing an NFL-best 191.5 yards per game. The Browns gave up 141 yards to Cincinnati in Week 1, including just seven in the second half, but still lost, 17-16. Cleveland has given up an NFL-best 45.5 rushing yards per game and just 2.1 rushing yards per attempt. “The biggest thing is our defensive line is much, much improved over last year and I think we’ve got back to our personality,” defensive coordinator Jim Schwartz said recently. “When we play our best, our D-line leads us there as our engine.” The Browns rank third in the league in passing defense, allowing just 146.0 yards per game. Cleveland has also gone 30 straight games without allowing a 300-yard passer, the longest active streak in the NFL.…
Share
BitcoinEthereumNews2025/09/18 00:41